Efficacy Data
Ensacove™ (ensartinib) is a second generation ALK TKI approved by the FDA for ALK+ NSCLC in patients who have not previously received an ALK-inhibitor.1
Sitemap
NCCN, National Comprehensive Cancer Network; 1L, first line; ALK, anaplastic lymphoma kinase; FDA, Food and Drug Administration.
